ERBB2 and breast carcinoma: The EMILIA study confirmed the role of T-DM1 in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane when compared with lapatinib plus capecitabine (PFS: 9.6 vs. 6.4 months; hazard ratio, 0.65; P < 0.001; OS: 30.9 months vs. 25.1 months; hazard ratio, 0.68; P < 0.001) [19].